48-year-old woman who underwent CEM to evaluate two masses (arrows) in right breast. CEM obtained in following order: (A) craniocaudal (CC) view of right breast; (B) CC view of left breast; (C) mediolateral oblique (MLO) view of right breast; and (D) MLO view of left breast. Degree of background parenchymal enhancement (BPE) increases over time after contrast agent injection. (A) CC view of right breast shows mild BPE, whereas subsequently obtained (B) CC view of left breast shows moderate BPE.

48-year-old woman who underwent CEM to evaluate two masses (arrows) in right breast. CEM obtained in following order: (A) craniocaudal (CC) view of right breast; (B) CC view of left breast; (C) mediolateral oblique (MLO) view of right breast; and (D) MLO view of left breast. Degree of background parenchymal enhancement (BPE) increases over time after contrast agent injection. (A) CC view of right breast shows mild BPE, whereas subsequently obtained (B) CC view of left breast shows moderate BPE. Based on criteria 1 reflecting only first obtained CC view, degree of BPE is classified as mild; based on criteria 2 reflecting both obtained CC views, degree of BPE is classified as moderate. Histopathologic assessment from subsequent biopsy demonstrated both masses to be invasive ductal carcinoma. 

 


January 27, 2023 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), both menstrual status and menstrual cycle time are associated with the degree of early background parenchymal enhancement (BPE) on contrast-enhanced mammography (CEM), which could influence CEM interpretations. 

“Clinical factors, including history of breast cancer or breast cancer treatment, breast density, menstrual status, and time of menstrual cycle, are associated with degree of early BPE on CEM,” wrote corresponding author Yajia Gu from the department of radiology at Fudan University Shanghai Cancer Center in China. “In premenopausal patients, degree of BPE is lowest on days 8–14 of the menstrual cycle.” 

This AJR accepted manuscript included 207 patients (median age, 46 years) who underwent CEM between April 2020 and September 2021. Two radiologists independently assessed BPE degree on CEM (minimal, mild, moderate, or marked) based on two criteria: using the first of four obtained views; using the first two of four obtained views. Reviewing electronic medical records for clinical factors, the radiologist pair reached consensus for breast density via CEM. 

Ultimately, degree of early BPE on CEM was negatively associated with age, history of breast cancer, chemotherapy or radiation therapy, as well as perimenopausal and postmenopausal status. Meanwhile, early BPE degree on this modality was positively associated with dense breasts and premenopausal status with irregular cycles.   

Acknowledging their retrospective study’s small sample size, given the potential impact of BPE on diagnostic performance, “the findings have implications for CEM scheduling and interpretation,” the authors of this AJR accepted manuscript added

For more information: www.arrs.org 

Related Breast Imaging Content: 

Single vs. Multiple Architectural Distortion on Digital Breast Tomosynthesis 

Today's Mammography Advancements  

Digital Breast Tomosynthesis Spot Compression Clarifies Ambiguous Findings  

AI DBT Impact on Mammography Post-breast Therapy  

ImageCare Centers Unveils PINK Better Mammo Service Featuring Profound AI  

Radiologist Fatigue, Experience Affect Breast Imaging Call Backs  

Fewer Breast Cancer Cases Between Screening Rounds with 3-D Mammography 

Study Finds Racial Disparities in Access to New Mammography Technology 

American College of Radiology (ACR) Launches Contrast-Enhanced Mammography Imaging Screening Trial (CMIST) in Collaboration With GE Healthcare and the Breast Cancer Research Foundation 


Related Content

News | Lung Imaging

May 31, 2024 — To further the fight against global lung cancer, Qure.ai, a leader in healthcare artificial intelligence ...

Time May 31, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 30, 2024 — RaySearch Laboratories AB announced the release of the latest version of RayCare, the next generation ...

Time May 30, 2024
arrow
News | Breast Imaging

May 28, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced a ...

Time May 28, 2024
arrow
News | Radiation Therapy

May 23, 2024 — RaySearch Laboratories AB and C-RAD announced a collaboration agreement, aiming at jointly developing ...

Time May 23, 2024
arrow
News | Artificial Intelligence

May 22, 2024 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, recently ...

Time May 22, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 21, 2024 — RaySearch Laboratories AB announced that the oncology information system RayCare* 2024A has been ...

Time May 21, 2024
arrow
News | Proton Therapy

May 21, 2024 — IBA, a world leader in particle accelerator technology, announced that it has signed a contract with the ...

Time May 21, 2024
arrow
News | Radiology Business

May 20, 2024 — Associated Medical Professionals of NY (A.M.P.) announced that internationally recognized radiation ...

Time May 20, 2024
arrow
News | ASTRO

May 17, 2024 — Registration opens today for the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting ...

Time May 17, 2024
arrow
News | Radiation Therapy

May 16, 2024 — Today marks a significant milestone in cancer care with the introduction of bipartisan federal ...

Time May 16, 2024
arrow
Subscribe Now